Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Drug Utilization, Anticholinergic Burden and Predictors of Length of Stay in a Psychiatric Hospital: A Retrospective Observational Study.Medicina (Kaunas, Lithuania) · 2026
   Observational
2. Antipsychotic dose is not associated with cognitive function in patients with schizophrenia aged under 40: a cross-sectional observational study with retrospective dose estimation.BMC psychiatry · 2026
   Observational
3. Nationwide trends in psychiatric prescription practices for drugs with putative cognitive adverse effects in schizophrenia spectrum and bipolar disorders from 2013 to 2022.Journal of pharmaceutical policy and practice · 2026
   Article
4. Short-term cognitive effects of anticholinergics in patients with neurogenic lower urinary tract dysfunction: A systematic review and meta-analysis.Biomedical reports · 2025
   Article
5. Impact of Anticholinergic Burden on Cognitive Functions in Individuals with Bipolar Disorder, Schizoaffective Disorder, and Schizophrenia.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
   Article
6. Anticholinergic load: A commonly neglected and preventable risk to cognition during schizophrenia treatment?Schizophrenia research. Cognition · 2024
   Article
7. An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.CNS drugs · 2024
   Review
8. Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort.Frontiers in pharmacology · 2024
   Article
9. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment.Molecular psychiatry · 2023
   Review
10. Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia.BMC psychiatry · 2023
    Article
11. Prescribing Trends for the Same Patients with Schizophrenia Over 20 Years.Neuropsychiatric disease and treatment · 2023
    Article
12. Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
13. Clinical Utility of Medication-Based Risk Scores to Reduce Polypharmacy and Potentially Avoidable Healthcare Utilization.Pharmaceuticals (Basel, Switzerland) · 2022
    Article
14. The Interplay between Vitamin D, Exposure of Anticholinergic Antipsychotics and Cognition in Schizophrenia.Biomedicines · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as